CN106432442B - 一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 - Google Patents
一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 Download PDFInfo
- Publication number
- CN106432442B CN106432442B CN201610892115.5A CN201610892115A CN106432442B CN 106432442 B CN106432442 B CN 106432442B CN 201610892115 A CN201610892115 A CN 201610892115A CN 106432442 B CN106432442 B CN 106432442B
- Authority
- CN
- China
- Prior art keywords
- lti1
- immune modulator
- lentinus tigrinus
- fip
- modulator fip
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000222451 Lentinus tigrinus Species 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims abstract description 14
- 239000013598 vector Substances 0.000 claims abstract description 6
- 239000002299 complementary DNA Substances 0.000 claims abstract description 5
- 238000000746 purification Methods 0.000 claims abstract description 5
- 238000005215 recombination Methods 0.000 claims abstract description 5
- 230000006798 recombination Effects 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims abstract description 4
- 238000000502 dialysis Methods 0.000 claims abstract description 3
- 230000006698 induction Effects 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 230000029087 digestion Effects 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 12
- 210000004698 lymphocyte Anatomy 0.000 abstract description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 210000000952 spleen Anatomy 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000007365 immunoregulation Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000002538 fungal effect Effects 0.000 description 15
- 230000002519 immonomodulatory effect Effects 0.000 description 14
- 240000008397 Ganoderma lucidum Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 244000000231 Sesamum indicum Species 0.000 description 4
- 235000003434 Sesamum indicum Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001480606 Ganoderma microsporum Species 0.000 description 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000057593 human F8 Human genes 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940047431 recombinate Drugs 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 240000006499 Flammulina velutipes Species 0.000 description 2
- 241001149422 Ganoderma applanatum Species 0.000 description 2
- 241001489087 Ganoderma fornicatum Species 0.000 description 2
- 241001480597 Ganoderma tsugae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001492489 Postia placenta Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006794 Volvariella volvacea Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000134914 Amanita muscaria Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000016640 Flammulina velutipes Nutrition 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- -1 N, N- methylene Chemical group 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000008976 Pterocarpus marsupium Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000004501 Volvariella volvacea Nutrition 0.000 description 1
- 241001231403 [Nectria] haematococca Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008970 bacterial immunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种虎皮香菇免疫调节蛋白Fip‑lti1及其制备方法和应用,免疫调节蛋白的氨基酸序列如SEQ ID NO.1所示。制备方法包括:(1)将虎皮香菇免疫调节蛋白的cDNA序列连入载体中,得到重组载体;(2)将上述重组载体转化宿主细胞,得到重组菌株;(3)培养上述重组菌株,诱导重组虎皮香菇免疫调节蛋白Fip‑lti1的表达;(4)经NI柱纯化、透析分离获取。所述免疫调节蛋白用于制备保健食品。本发明通过体外重组得到的虎皮香菇免疫调节蛋白Fip‑lti1能够明显促进脾淋巴细胞增殖、促进肿瘤坏死因子TNF‑α的表达等免疫调节作用,因此,在提高机体免疫力方面具有应用潜力。
Description
技术领域
本发明属于真菌免疫调节蛋白领域,特别涉及一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用。
背景技术
真菌免疫调节蛋白(Fungal immunomodulatory protein,FIP)是从高等担子菌中分离得到的一类具有免疫调节活性的小分子蛋白质。1989年,日本学者Kino从灵芝(Ganoderma lucidum)子实体中分离到第一个真菌免疫调节蛋白,命名为Ling Zhi-8(LZ-8),并对其基因序列、氨基酸顺序和免疫生理活性进行了测定(Kino K,1989,J BiolChem)。通过体外实验发现,真菌免疫调节蛋白可以促进小鼠脾细胞和人类周边血淋巴细胞的增生(Hsieh KY,2003,Clin Exp Allergy),促进T淋巴细胞分泌表达黏附分子ICAM(WuCT,2011,Carcinogenesis),增强IL-2,TNF-α和IFN-γ的分泌水平(Li QZ,2011,Crit RevBiotechnol),从而提高机体免疫力。同时在动物实验中还观察到真菌免疫调节蛋白可以抑制小鼠产生全身性过敏,或降低局部性免疫过敏的发生率(Lin YL,2009,J LeukocyteBiol),并且可以减轻一型糖尿病的病情(Kino K,1990,Diabetologia),过敏和一型糖尿病都是由于机体免疫系统紊乱所致,而真菌免疫调节蛋白具有调节机体免疫系统恢复正常功能的作用。在抗癌方面,真菌免疫调节蛋白对于HL60肿瘤细胞具有很强的抗肿瘤活性(Huang L,2009,Proteins)。并且相对于许多成分复杂难解或化学结构不清楚(如灵芝多糖)的中草药来说,真菌免疫调节蛋白具有简单的化学结构,完全具备成药的条件。因此,真菌免疫调节蛋白拥有良好的临床应用前景和药用保健价值。
目前,已经从灵芝(G.lucidium)、金针菇(Flammulina velutipes)、草菇(Volvariella volvacea)、松杉灵芝(G.tsugae)、紫芝(G.japoncium)、小孢子灵芝(G.microsporum)、甜灵芝(G.sinense)、拱状灵芝(G.fornicatum)、绵腐卧孔菌(Postiaplacenta)和赤球丛赤壳(Nectria haematococca)中发现真菌免疫调节蛋白,但是还未有在毒蝇鹅膏(Amanita muscaria)中发现真菌免疫调节蛋白的相关报道。在大型真菌中挖掘新型真菌免疫调节蛋白资源,对于我国进一步开发有关真菌免疫调节蛋白药物和保健食品,提高我国在食用菌资源开发方面的核心竞争力具有非常重要的意义。
发明内容
本发明所要解决的技术问题是提供一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用,该虎皮香菇免疫调节蛋白Fip-lti1能够明显促进脾淋巴细胞增殖、促进肿瘤坏死因子TNF-α的表达等免疫调节作用,因此,在提高机体免疫力方面具有应用潜力。
本发明的一种虎皮香菇免疫调节蛋白Fip-lti1,所述免疫调节蛋白的氨基酸序列如SEQ ID NO.1所示。
本发明的一种编码虎皮香菇免疫调节蛋白Fip-lti1的基因,所述基因的序列如SEQ ID NO.2所示。
将虎皮香菇免疫调节蛋白Fip-lti1的cDNA序列在GenBank中进行BLAST比对,没有发现与其相似的基因序列,而将其氨基酸序列在NCBI的无冗余蛋白序列数据库(nr)中进行BLAST比对发现,该蛋白与来源于小孢子灵芝(G.microsporum)免疫调节蛋白的相似性达到55%,与来自于赤芝(Ganoderma lucidum)免疫调节蛋白LZ-8的相似性为50%。
本发明的一种虎皮香菇免疫调节蛋白Fip-lti1基因的载体。
优选的,所述载体为pET-32a。
将本发明的虎皮香菇免疫调节蛋白Fip-lti1基因插入到表达载体合适的限制性酶切位点之间,使其核苷酸序列可操作的与表达调控序列相连接。优选的,将虎皮香菇免疫调节蛋白Fip-lti1基因插入到pET-32a上的BamHI和XhoI限制性酶切位点之间,得到重组载体pET-Fip-lti1。
本发明的一种虎皮香菇免疫调节蛋白Fip-lti1基因的重组菌株。
优选的,所述重组菌株为Rosetta-Fip-lti1。
本发明的一种虎皮香菇免疫调节蛋白Fip-lti1的制备方法,包括:
(1)将虎皮香菇免疫调节蛋白的cDNA序列连入载体中,得到重组载体;
(2)将上述重组载体转化宿主细胞,得到重组菌株;
(3)培养上述重组菌株,诱导重组虎皮香菇免疫调节蛋白Fip-lti1的表达;
(4)经NI柱纯化、透析分离获取所表达的虎皮香菇免疫调节蛋白Fip-lti1。
所述步骤(2)中的宿主细胞为大肠杆菌Rosetta细胞。
本发明的一种虎皮香菇免疫调节蛋白Fip-lti1的应用,所述免疫调节蛋白用于制备保健食品。
本发明运用基因工程手段获得,以及用于产业化生产虎皮香菇免疫调节蛋白Fip-lti1产品都未见报道。本发明首次提供了虎皮香菇免疫调节蛋白Fip-lti1,该蛋白对脾淋巴细胞具有催化分裂的作用,可作用于保健品和医药等工业。根据本发明的技术方案就可以实现利用基因工程手段生产虎皮香菇免疫调节蛋白Fip-lti1。
有益效果
本发明虎皮香菇免疫调节蛋白Fip-lti1能够明显促进脾淋巴细胞增殖、促进肿瘤坏死因子TNF-α的表达等免疫调节作用,因此,在提高机体免疫力方面具有应用潜力;可以制备出新型的提高人体免疫力的保健食品,防治由于免疫力下降所导致的疾病的危害,具有良好的应用前景。
附图说明
图1为本发明虎皮香菇免疫调节蛋白Fip-lti1氨基酸序列与其它真菌免疫调节蛋白氨基酸序列比对结果;
图2为本发明pET-Fip-lti1质粒图谱;
图3为本发明虎皮香菇免疫调节蛋白Fip-lti1表达的SDS-PAGE分析;其中,1为包涵体;2为上清;M为分子量标准;
图4为本发明虎皮香菇免疫调节蛋白Fip-lti1的分离纯化;
图5为本发明虎皮香菇免疫调节蛋白Fip-lti1促进脾淋巴细胞增殖实验;
图6为本发明虎皮香菇免疫调节蛋白Fip-lti1促进肿瘤坏死因子TNF-α的表达。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
下述是实施例中所用的试验材料,如无特殊说明,均为常规生化试剂公司买得。以下实施例中的定量实验,均设置三次重复实验,结果取平均值。
1.细胞株:Rosetta感受态,DH5a感受态。
2.动物:清洁级ICR小鼠,体重18~22g,购于扬州大学实验动物中心。
3.试剂盒、酶类、生化试剂和仪器:
试剂盒:天根质粒提取试剂盒,天根蛋白定量检测试剂盒,上海生工PCR产物回收试剂盒,PCR引物合成和基因测序均由上海生工完成。TNF-αElisa检测试剂盒,CD4+CD62L+TCell分离试剂盒购于美国BD。
酶类:Takara常规内切酶,Takara DNA T4连接酶,东盛TaqDNA聚合酶。
仪器:艾本德微量加样器、赛默飞世尔离心机、酶联免疫分析仪,上海天能凝胶成像仪、水平电泳槽、垂直电泳槽,江阴诺源恒温培养摇床,新芝超声破碎仪,Biorad电转仪,晶格PCR仪,美国Thermo scientific细胞培养箱、多功能酶标仪,苏州金净生物安全柜,上海蔡康倒置显微镜。
生化试剂:
国药冰乙酸、丙三醇(甘油)、无水乙醇、异丙醇、甲醇、甘氨酸、Tris、氢氧化钠、EDTA、氯化钠、氯化钾、十二水合磷酸二氢钠、磷酸二氢钾、咪唑、脲、盐酸胍;生工NI树脂、丙烯酰胺、N,N-亚甲叉丙烯酰胺、IPTG;Oxdine胰蛋白胨、酵母提取物;Solarbio氨苄青霉素、卡那抗生素;SDS、β-巯基乙醇、考马斯亮蓝R-250、AP;美国sigmaMTT。
4.培养基:生工LB培养基,美国GIBCORPMI 1640培养基,胎牛血清。
实施例1
虎皮香菇免疫调节蛋白Fip-lti1基因序列信息与同源性分析:
虎皮香菇免疫调节蛋白Fip-lti1cDNA序列为339bp,详细序列见SEQ ID NO.2。根据cDNA序列推导出Fip-lti1氨基酸序列,共112个氨基酸残基,分子量12.61kDa,理论等电点(pI)为8.66,不稳定系数为11.36,脂肪族系数为79.2,详细序列见SEQ ID NO.1所示序列。
将虎皮香菇免疫调节蛋白Fip-lti1氨基酸序列用BLAST程序在Non-redundantGenBank数据库中进行蛋白质同源性检索,结果发现它与来源于小孢子灵芝(G.microsporum)免疫调节蛋白的相似性达到61%,与来自于平盖灵芝(G.applanatum)免疫调节蛋白的相似性为60%,与来自于赤芝(G.lucidum)免疫调节蛋白LZ-8的相似性为58%,与金针菇(F.velutipes)免疫调节蛋白相似性为54%,与绵腐卧孔菌(P.placenta)免疫调节蛋白相似性为51%,如图1所示。由此可见,虎皮香菇免疫调节蛋白Fip-lti1与真菌免疫调节蛋白家族在蛋白水平上存在较高的同源性,是一种真菌免疫调节蛋白。
实施例2
虎皮香菇免疫调节蛋白Fip-lti1基因的合成与表达:
委托上海生工生物工程有限公司完成基因的碱基序列合成,合成的序列构建到克隆载体pUC57上,转化克隆菌株DH5a,提取质粒,以双酶切(BamHI和XhoI)消化后,琼脂糖凝胶电泳,回收Fip-lti1基因片段,以连接酶(T4ligase)连接到以BamHI和XhoI消化的pET32a载体上,表达载体pET-Fip-lti1转化到表达菌株Rosetta。挑取单克隆,LB液体培养基培养,次日,菌种以1:50扩大培养800mL,37℃培养至OD600=0.4-0.6,加入0.5mM的IPTG,37℃诱导表达5h。经0.5mM的IPTG,37℃诱导表达5h。如图2所示,将Fip-lti1基因片段构建到表达载体pET32a上。
实施例3
重组虎皮香菇免疫调节蛋白Fip-lti1的分离与纯化:
8000rpm、4℃离心5min,收集诱导表达的菌株,加100mL破碎液进行超声波裂解。裂解条件:温度冰浴、功率60%、超声2s、间隔2s、时间15min。12000rpm、4℃离心15min,收集上清和沉淀。SDS-PAGE检测,判断目的蛋白的表达形式。目的蛋白Fip-lti1以可溶性形式存在。过NI柱纯化,收集流穿液、洗脱液,SDS-PAGE检测蛋白纯化效果。如图3、4所示诱导表达的蛋白通过SDS-PAGE鉴定,大小正确。
实施例4
重组虎皮香菇免疫调节蛋白Fip-lti1真菌免疫调节蛋白的脾淋巴细胞增殖试验:
(1)脾细胞悬液制备:BALB/c小鼠购得后饲养1周进行免疫学实验。无菌条件下脱颈椎处死,立即切除脾脏,加适量PBS研磨,以100目不锈钢网滤过,并加入红细胞裂解液5min除去溶血的红细胞,1200r/min离心5min,弃上清,加PBS重复洗涤2次。然后加入CD4+CD62L+T Cell分离试剂盒,即得到纯度大于90%的淋巴细胞。淋巴细胞用10%胎牛血清,RPMI 1640培养基进行培养。
(2)淋巴细胞增殖实验:于96孔板中,每孔加100μL脾细胞悬液(1×107个/mL),实验设置空白组,刀豆蛋白A(ConA)组,Fip-lti1组和LZ-8阳性对照组。ConA组、Fip-lti1组及LZ-8组分别加入20μL浓度为5μg/mL的ConA作用6h,然后Fip-lti1组和LZ-8组分别加入终浓度为100μM的Fip-lti1和LZ-8,每孔各100μL。作用12h,每组设置4个复孔。达到作用时间后,向上述细胞板中各加药孔入10μL MTT试剂(MTT需避光,放入培养箱中,4h后弃去孔中液体加入150μL DMSO,震荡使结晶物充分溶解,在多功能酶标仪A570nm测定吸光度,计算细胞增殖情况。
如图5所示,虎皮香菇免疫调节蛋白Fip-lti1能显著促进脾淋巴细胞的增殖,其效果与LZ-8相当。
实施例5
重组虎皮香菇免疫调节蛋白Fip-lti1的促肿瘤坏死因子TNF-α的表达:
脾细胞悬液制备及细胞铺板方法与细胞增殖实验一致。
(1)标准品的稀释与加样:在酶标包被板上设标准品孔10孔,在第一、第二孔中分别加标准品100μL,然后在第一、第二孔中加标准品稀释液50μL,混匀;然后从第一孔、第二孔中各取100μL分别加到第三孔和第四孔,再在第三、第四孔分别加标准品稀释液50μL,混匀;然后在第三孔和第四孔中先各取50μL弃掉,再各取50μL分别加到第五、第六孔中,再在第五、第六孔中分别加标准品稀释液50μL,混匀;混匀后从第五、第六孔中各取50μL分别加到第七、第八孔中,再在第七、第八孔中分别加标准品稀释液50μL,混匀后从第七、第八孔中分别取50μL加到第九、第十孔中,再在第九第十孔分别加标准品稀释液50μL,混匀后从第九第十孔中各取50μL弃掉。(稀释后各孔加样量都为50μL,浓度分别为(300ng/L,200ng/L,100ng/L,50ng/L,25ng/L)。
(2)加样:分别设空白孔(空白对照孔不加样品及酶标试剂,其余各步操作相同)、待测样品孔。在酶标包被板上待测样品孔中先加样品稀释液40μL,然后再加待测样品10μL(样品最终稀释度为5倍)。将样品加于酶标板孔底部,尽量不触及孔壁,轻轻晃动混匀。
(3)温育:用封板膜封板后置37℃温育30min。
(4)配液:将20倍浓缩洗涤液用蒸馏水20倍稀释后备用。
(5)洗涤:小心揭掉封板膜,弃去液体,甩干,每孔加满洗涤液,静置30s后弃去,如此重复5次,拍干。
(6)加酶:每孔加入酶标试剂50μL,空白孔除外。
(7)温育:操作同(3)。
(8)洗涤:操作同(5)。
(9)显色:每孔先加入显色剂A 50μL,再加入显色剂B 50μL,轻轻震荡混匀,37℃避光显色15min.
(10)终止:每孔加终止液50μL,终止反应(此时蓝色立转黄色)。
(11)测定:以空白孔调零,450nm波长依序测量各孔的吸光度(OD值)。测定应在加终止液后15min以内进行。
如图6所示,虎皮香菇免疫调节蛋白Fip-lti1能显著促进肿瘤坏死因子TNF-α水平表达,其效果与LZ-8相当。
Claims (9)
1.一种虎皮香菇免疫调节蛋白Fip-lti1,其特征在于:所述免疫调节蛋白的氨基酸序列如SEQ ID NO.1所示。
2.一种编码如权利要求1所示的虎皮香菇免疫调节蛋白Fip-lti1的基因,其特征在于:所述基因的序列如SEQ ID NO.2所示。
3.一种含如权利要求2所述的虎皮香菇免疫调节蛋白Fip-lti1基因的载体。
4.根据权利要求3所述的一种虎皮香菇免疫调节蛋白Fip-lti1基因的载体,其特征在于:将虎皮香菇免疫调节蛋白Fip-lti1基因插入到pET-32a上的BamHI和XhoI限制性酶切位点之间,得到重组载体pET-Fip-lti1。
5.一种含如权利要求2所述的虎皮香菇免疫调节蛋白Fip-lti1基因的重组菌株。
6.根据权利要求5所述的一种虎皮香菇免疫调节蛋白Fip-lti1基因的重组菌株,其特征在于:所述重组菌株为Rosetta-Fip-lti1。
7.一种虎皮香菇免疫调节蛋白Fip-lti1的制备方法,包括:
(1)将编码如权利要求1所述虎皮香菇免疫调节蛋白的cDNA序列连入载体中,得到重组载体;
(2)将上述重组载体转化宿主细胞,得到重组菌株;
(3)培养上述重组菌株,诱导重组虎皮香菇免疫调节蛋白Fip-lti1的表达;
(4)经NI柱纯化、透析分离获取所表达的虎皮香菇免疫调节蛋白Fip-lti1。
8.根据权利要求7所述的一种虎皮香菇免疫调节蛋白Fip-lti1的制备方法,其特征在于:所述步骤(2)中的宿主细胞为大肠杆菌Rosetta细胞。
9.一种如权利要求1所述的虎皮香菇免疫调节蛋白Fip-lti1的应用,其特征在于:所述免疫调节蛋白用于制备保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610892115.5A CN106432442B (zh) | 2016-10-12 | 2016-10-12 | 一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610892115.5A CN106432442B (zh) | 2016-10-12 | 2016-10-12 | 一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106432442A CN106432442A (zh) | 2017-02-22 |
CN106432442B true CN106432442B (zh) | 2019-07-05 |
Family
ID=58174360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610892115.5A Active CN106432442B (zh) | 2016-10-12 | 2016-10-12 | 一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106432442B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107118263B (zh) * | 2017-04-08 | 2020-07-03 | 张喜田 | 重组灵芝免疫调节蛋白突变体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104817635A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo80及其制备方法 |
CN104817637A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo78及其制备方法 |
CN104817634A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo98及其制备方法 |
CN104892735A (zh) * | 2015-04-30 | 2015-09-09 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo82及其制备方法 |
-
2016
- 2016-10-12 CN CN201610892115.5A patent/CN106432442B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104817635A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo80及其制备方法 |
CN104817637A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo78及其制备方法 |
CN104817634A (zh) * | 2015-04-30 | 2015-08-05 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo98及其制备方法 |
CN104892735A (zh) * | 2015-04-30 | 2015-09-09 | 上海市农业科学院 | 一种草菇免疫调节蛋白FIP-vvo82及其制备方法 |
Non-Patent Citations (1)
Title |
---|
hypothetical protein NECHADRAFT_88285 [[Nectria] haematococca mpVI 77134];Coleman,J.J.等;《Genbank database》;NCBI BLAST;20100814;ACCESSION NO. XP_003043654 * |
Also Published As
Publication number | Publication date |
---|---|
CN106432442A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103980354B (zh) | 真菌免疫调节蛋白FIP-ppl及其基因 | |
Li et al. | Identification and functional characterization of a novel fungal immunomodulatory protein from Postia placenta | |
CN102618552B (zh) | 一种重组艾塞那肽的生产工艺 | |
CN105106945B (zh) | 一种幽门螺旋杆菌四价毒力因子多表位疫苗及其制备方法 | |
CN104725517B (zh) | 一种提高酵母细胞表面目的蛋白展示量的方法 | |
CN106397610A (zh) | 细粒棘球蚴多表位融合诊断抗原蛋白的制备方法及其应用 | |
CN104402975B (zh) | 抗衰老短肽及其制备方法 | |
Al Atalah et al. | Expression analysis of the nucleocytoplasmic lectin ‘Orysata’from rice in Pichia pastoris | |
Shao et al. | Characterization of a novel fungal immunomodulatory protein, FIP-SJ75 shuffled from Ganoderma lucidum, Flammulina velutipes and Volvariella volvacea | |
CN106432442B (zh) | 一种虎皮香菇免疫调节蛋白Fip-lti1及其制备方法和应用 | |
CN106496311B (zh) | 一种漏斗大孔菌免疫调节蛋白Fip-par1及其制备方法和应用 | |
CN108192910A (zh) | 培育降血糖和降血栓的转基因植物 | |
CN102199201B (zh) | 灵芝属内重组的真菌免疫调节蛋白基因、该基因编码的蛋白及其应用 | |
CN106432441B (zh) | 一种虎皮香菇免疫调节蛋白Fip-lti2及其制备方法和应用 | |
CN103626877A (zh) | 含ny-eso-1的融合蛋白、制备方法及应用 | |
CN102898514B (zh) | 重组人神经生长因子缺失突变体及其制备方法和用途 | |
CN107540739A (zh) | 一种肿瘤靶向性多肽 | |
CN106478812A (zh) | 丝氨酸蛋白酶抑制剂‑3及其功能、制备方法和应用 | |
CN103360497A (zh) | 一种新型抗肿瘤融合蛋白疫苗及其制备方法和应用 | |
CN106046128B (zh) | 具有抗肿瘤活性的真菌免疫调节蛋白FIP-sch3 | |
CN106243204A (zh) | 一种毒蝇鹅膏免疫调节蛋白Fip‑amu1及其制备方法和应用 | |
CN104593401B (zh) | 一种应用pCold载体表达可溶性广州管圆线虫galectin‑1蛋白的方法 | |
CN104480126A (zh) | 一种卵形鲳鲹过氧化物还原酶基因 | |
CN106188255B (zh) | 一种真菌免疫调节蛋白FIP-dsq2及其应用 | |
Yu et al. | Characterization, Recombinant Production, and Bioactivity of a Novel Immunomodulatory Protein from Hypsizygus marmoreus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |